IN-VITRO AND IN-VIVO GROWTH OF B16F10 MELANOMA-CELLS TRANSFECTED WITHINTERLEUKIN-4 CDNA AND GENE-THERAPY WITH THE TRANSFECTANT

In an attempt to develop the most effective cytokine gene therapy, we transfected mouse interleukin(IL)-2, mouse IL-4, and human IL-6 cDNAs into mouse melanoma cells, B16F10. Transfection with IL-4 cDNA decreas ed the tumorigenicity of B16F10 most strongly. We investigated whether gene therapy with IL-4-transfected B16F10 cells was possible. Flowcyt ometric analysis showed that major histocompatibility complex class I and II expression in B16F10 and IL-4-cDNA-transfected B16F10(B16F10-IL 4) cells did not differ. Doubling times of B16F10 and B16F10-IL4 were 20.1 and 21.1 h respectively. The growth of B16F10 cells was retarded if C57BL/6 mice were inoculated with B16F10-IL4 at the contralateral s ides. When 5 x 10(5) B16F10 cells were transplanted subcutaneously int o the flanks of C57BL/6 mice, they all developed a tumor mass, whereas no tumor masses formed in those transplanted with B16F10-IL4 cells wi thin 60 days. No nude, severe combined immunodeficient or beige mice w ere able to reject parental B16F10 or B16F10-IL4 cells, although, B16F 10-IL4 tumor growth in all these immunodeficient mice was slower than that of B16F10. Therefore, we concluded that T and natural killer cell s are necessary for rejection of B16F10-IL4 tumor cells.